Tetraphase Pharmaceuticals, Inc. (TTPH)

[Abdullah3]

Item 2.02 Results of Operations and Financial Condition.

On July 27, 2017, in a preliminary prospectus supplement filed with the SEC, the Company disclosed that its cash and cash equivalents as of June 30, 2017 was approximately $118.2 million


On January 17, 2017, we entered into sales agreement with a sales agent in respect of an“at-the-market” offering program. On July 7, 2017, we entered into an amendment to the sales agreement to increase the maximum aggregate offering price of the shares of our common stock that we may issue and sell from time to time under the sales agreement from $40,000,000 to $80,000,000. As of July 27, 2017, we had sold 3,935,450 shares of our common stock under the sales agreement at an average price of $7.78 per share for an aggregate offering price of $30.6 million, before deducting sales commissions and offering expenses, which includes 611,865 shares sold on July 26, 2017 at an average price of $7.79 per share for an aggregate offering price of approximately $4.76 million, before deducting sales commissions and offering expenses.

the Company expects to receive net proceeds from the offering of approximately $60.9 million (or approximately $70.1 million if the Underwriters exercise in full their option to purchase additional shares of common stock).

Which means they have $118.2M + $35.4M + $60.9M or $70.1M=$214.5M or $223.7M